Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Exclusion Criteria

• •History of significant liver disease (eg, alcoholic liver disease, viral hepatitis, etc.) or liver transplant.
• •Presence of cirrhosis on any prior liver biopsy (stage 4 fibrosis).
• •Excessive consumption of alcohol.
• •Use of any insulin (injectable or inhaled), SGLT-2 inhibitor or glucagon-like peptide 1 (GLP-1, injectable or oral) products for \> 7 days within 3 months of screening.
• •Weight loss \> 10% in the 6 months prior to screening or \> 5% during screening.
• •Use of drugs historically associated with causing NAFLD for more than 4 consecutive weeks within 12 months prior to screening.
• •Concomitant use of drugs that are strong or moderate CYP3A4 inhibitors.
• •Concomitant consumption of grapefruit juice with the study drug.
• •History of diabetic ketoacidosis (DKA) within 1 month prior to the Screening Visit, or more than 2 episodes within 6 months prior to the Screening Visit.
• •History of \> 2 episodes of urosepsis or pyelonephritis within 5 years of screening.